Press Releases

Latest News & Events

12/03/2021

Disruptive Applications in Oncology and Beyond

23/12/2020

Seven severely ill patients treated with Enlivex’s Allocetra, have fully recovered.

05/11/2020

The Staging of a New Disease and Its Implications for Treatment Options

01/10/2020

All five in serious or critical condition before being treated with Allocetra

16/02/2020

The innovative therapy is based on the research of Prof. Dror Mevorach

Investment Highlights

Paradigm shifting immunotherapy For complex, unmet clinical need indications

Macrophage reprogramming, unmet medical need indications
Off-the-shelf, universal cell therapy for resetting macrophages back to their ”manufacturer settings”, and away from “disease settings”

Advanced clinical-stage pipeline with promising phase 2a results

Advanced clinical-stage pipeline
Phase IIb macrophage reprogramming for sepsis; Phase II COVID-19 Phase Ib macrophage reprogramming for solid tumor scheduled for 2021

Advanced clinical-stage pipeline with promising phase 2a results

Short regulatory approval pathway
Specialized regulation in Europe potentially enabling post-Phase II marketing approval in sepsis and COVID-19

Short regulatory approval pathway FDA & EU orphan designations; Specialized life-threatening regulation in Europe potentially enabling post-Phase II marketing approval

Multi-billion dollar underserved markets
Sepsis | Solid Tumors | COVID-19 | ARDS

Strong leadership Previously founded and managed PROLOR Biotech, sold For $560M; Signed partnership with Pfizer, $295 Million down payment

Strong leadership
Previously founded and managed PROLOR Biotech, a $560M exit event; Signed partnership with Pfizer, $295 Million down payment

Cash balance $30 Million invested; Expected cash balance of 2.5 Years at closing, Next clinical milestone within 12 months

Cash balance
~$60 million invested; Cash balance supporting multiple clinical milestones within 18-24 months; Funded through Q1 2023

SEC Filings

Date Form Description Download

Corporate Governance

Charter of the Audit Committee of the Board of Directors download
Charter of the Compensation Committee of the Board of Directors download
Code of Business Conduct and Ethics download
Disclosure Policy download
Employee Complaint Procedures for Accounting and Auditing Matters download
Insider Trading Policy download
Download our company overview

Find out more

14 Einstein St. Nes-Ziona, Israel, 7403618
T +972.2.6708072  |  F +972.2.6708070
info@enlivex.com